A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Inclusion Criteria:

• Histologically or cytologically documented NSCLC that is locally advanced ormetastatic according to Version 8 of the IASLC Staging Manual in Thoracic Oncology.

• Documented epidermal growth receptor factor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type status as determined at a local laboratory.

• Documented radiological PD whilst on or after receiving the most recent treatmentregimen.

• Eligible for second- or third-line therapy and must have received an anti-PD-(L)1therapy and a platinum doublet containing therapy for locally advanced or metastaticNSCLC either separately or in combination.

• Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO)performance status of 0 or 1.

• Adequate organ function and marrow reserve

• Minimum life expectancy of 12 weeks.

• Body weight > 30 kg and no cancer-associated cachexia.

• Negative pregnancy test (serum test) for women of childbearing potential (WOCBP).

Exclusion Criteria:

• Participant with mixed SCLC and NSCLC histology.

• History of another primary malignancy except for malignancy treated with curativeintent with no known active disease ≥ 5 years before the first dose of studyintervention.

• Persistent toxicities (CTCAE Grade > 2) caused by previous anticancer therapy.

• Active or prior documented autoimmune or inflammatory disorders.

• Participants who have received more than one line of prior anti-PD-(L)1, eitheralone or in any combination.

• Participants:

1. Must not have experienced a toxicity that led to permanent discontinuation ofthe prior anti-PD(L)1 therapy.

2. All AEs while receiving prior anti-PD(L)1 therapy must have completelyresolved.

3. Must not have experienced a Grade ≥ 3 immune-mediated adverse event (imAE) oran immune-related neurologic or ocular AE of any grade while receiving prioranti-PD(L)1 therapy.

4. Must not have required the use of additional immunosuppression other thancorticosteroids for the management of an AE, not have experienced recurrence ofan AE if re-challenged, and not currently require maintenance doses of > 10 mgprednisone or equivalent per day.

• Participants who have received more than one prior line of platinum-basedchemotherapy in metastatic setting.

• Participants who have received a prior ataxia telangiectasia and Rad3-relatedprotein (ATR) inhibitor.